RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on PTC Therapeutics (NASDAQ:PTCT), but lowered the price target from $49 to $26.
September 18, 2023 | 12:24 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
RBC Capital has maintained its 'Sector Perform' rating on PTC Therapeutics, but has significantly lowered the price target from $49 to $26.
The significant reduction in the price target for PTC Therapeutics by RBC Capital could negatively impact investor sentiment and potentially lead to a short-term decrease in the stock price. The 'Sector Perform' rating suggests that the stock is expected to perform in line with the sector, but the lowered price target indicates a less optimistic outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100